You are here: Industry Insights > Exelixis

News List

Exelixis’ Cabometyx approved in second-line liver cancer in US pharmaphorum
January 16, 2019
Exelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a second line therapy option for patients previously treated with Bayer’s Nexavar.
Exelixis Announces U.S. FDA Approval of CABOMETYX (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma firstwordpharma
January 15, 2019
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc.(NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously treated wi
Exelixis and Ipsen Initiate Phase 3 Pivotal Trial for Advanced Hepatocellular Carcinoma Treatment americanpharmaceuticalreview
December 06, 2018
Evelix’s, Inc. and Ipsen have announced the initiation of COSMIC-312, a phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with.....
Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (Cabozantinib) for Previously biospace
March 16, 2018
Exelixis, Inc. today announced it has completed the submission of a supplemental New Drug Application (sNDA)
FDA grants priority review for Exelixis’ Cabometyx to treat advanced RCC pharmaceufical-technology
October 19, 2017
Cabometyx is the tablet formulation of cabozantinib available in 20mg, 40mg or 60mg doses and its targets include MET, AXL and VEGFR-1, -2 and -3.

Previous page 1 2 Next page